Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand